CTi Biopharma Corp

CTi Biopharma — Cell Therapeutics — Merger or Acquisition (June 2003)

4 slides from CTi Biopharma's merger presentation, Jun 20, 2003

  1. Slide 1: Oncology Pipeline

    TRISENOX® TRISENOX® TRISENOX® APL label, > 40 trials Potential MDS label Potential myeloma label XYOTAX™ XYOTAX™ XYOTAX™ Phase III trials Potential NDA Potential NSCLC label Pixantrone Pixantrone Pixantrone Phase III trials Potential NDA Potential aggressive NHL label Oncology Pipeline Preclinical P

  2. Slide 2: Doxorubicin, Mitoxantrone, Pixantrone

    Doxorubicin Mitoxantrone Pixantrone

  3. Slide 3: Pixantrone: Experimental cardiotoxicity

    Pixantrone Experimental cardiotoxicity

  4. Slide 4: Pixantrone: Target product profile

    Pixantrone Target product profile

Cell Therapeutics — Merger or Acquisition (June 2003) on 6ix